Oppenheimer increased its price target for Trevi Therapeutics Inc. (NASDAQ:TRVI) to $23 from $20, while maintaining an ...

Oppenheimer maintained its Outperform rating on Trevi Therapeutics, Inc. (NASDAQ:TRVI) shares and lifted the price target ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

NEW HAVEN, Conn., June 3, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral ...

Trevi's Haduvio met its primary endpoint in a Phase 2b trial for IPF-related chronic cough, with statistically significant ...

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which ...

President and CEO of Trevi Therapeutics. "Chronic cough is one of the most debilitating comorbidities for patients with IPF, impacting an estimated 85% of these patients. There are no approved ...

B. Riley restated their buy rating on shares of Trevi Therapeutics (NASDAQ:TRVI – Free Report) in a research note issued to investors on Wednesday morning,Benzinga reports. B. Riley currently ...

Morgan Stanley, Leerink Partners, Stifel and Cantor are acting as joint book-running managers for the offering.